| خلاصه مقاله | • In order to treat multidrug-resistant (MDR) bacterial infections, the current
choices are restricted(1) so it is one of the main challenges in medicine especially
in immunocompromised patients and people who have excessive use of
antibiotics(2). One the newest approach to combat this issue is Fecal microbiota
transplantation (FMT) that is also used against Clostridium difficile infection(1).
The aim of this study was search the treatments against MDR klebsiella
pneumoniae by using FMT.• Materials & Methods
• In order to answer this topic, our search was performed in google scholar from
December 24, 2023 to December 29, 2023 and first of all to get the
comprehensive results, keywords of fecal microbiota transplantation, multi-drug
resistant, Klebsiella pneumoniae and treat were selected.• Results
• There isn’t any both of extended spectrum β-lactamase(ESBL) and K. pneumoniae in urine and faeces after using FMT to
treat patients that were suffering from urinary tract infections(3)also after using FMT, there isn’t any pathogen that some
of them cause sepsis. It has been determined that Bacteroides and Firmicutes are the most abundant microbiota of donor
by using 16S rRNA sequencing (2) and butyrate-producing anaerobic microorganisms like Faecalibacterium prausnitzii,
Roseburia hominis, Coprococcus eutactus and Barnesiella spp by reducing the immune responses demonstrate the best
results as super-donor(4). Klebsiella pneumoniae and Escherichia coli are the most microorganisms which are classified in
carbapenem-resistant Enterobacterales that FMT is a useful tool to remove their infections(5).FMT is effective not only in
eradicating ESBL and carbapenemase-producing Enterobacteriaceae infections, but also is against vancomycin-resistant
Enterococci or methicillin-resistant Staphylococcus aureus infections(1).• Conclusion
• In order to treat MDR klebsiella pneumoniae infections, FMT is one of the newest
approach to combat this problem which type of the donor microbiota is so
effective to get the best results but we must consider its safety especially in
immunocompromised patients so, FMT needs more evaluations. |